DeviceTalks Boston: Here’s what you need to know


How to rethink your medical device company

In the medtech market, startups have to be flexible; the startup pivot is crucial. “Companies have to morph as they go,” said Maria Palasis, CEO of bioresorbable drug delivery system company 480 Biomedical.

Palasis explained that startups, and even mature companies should expect to shift their technology in one way or another through the course of getting a product to market. It might mean changing focus to address an unmet need in a different disease state or alter the technology to more effectively impact the disease. The process is expected and built into lean startup models.

Read the full story.

(Palasis will be speaking in the CEO Sessions panel at DeviceTalks Boston on Oct. 2,  about technologies that are changing the paradigm of care.)

And here are more articles with DeviceTalks Boston speakers:

Is there a digital health solution for treating pain? (Frank McGillin, NeuroMetrix’s chief commercial officer)

Want to sell your medtech startup? Be one of these three things (Peter Stebbins, Johnson & Johnson Innovation)

GI Dynamics CEO Scott Schorer is optimistic about Endobarrier’s future: Here’s why

NxStage Medical’s Todd Snell talks FDA, Brexit & regulatory strategy

Did Congress just kill medical device innovation? (Vascular Science’s Mike Drues)


How do you know your technology is disruptive enough to break conventional wisdom?

textadimage Stan Rowe knows a little something about bringing disruptive technology to market. The current Edwards Lifesciences CSO was in on the ground floor of two of medtech's most disruptive treatments, stents and transcatheter aortic valve replacement.

On December 12th, Rowe will sit down with MassDevice editor Brad Perriello for a long ranging discussion about the inside story on how these technologies came to market and what Rowe learned along the way.

Register now with the code "TAVR" and save 15% today.

Pages: 1 2 3 4 5 6 7 8

Speak Your Mind